Comparison 13. OnabotulinumtoxinA 40 units versus placebo one cycle of treatment for forehead lines and glabellar lines.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
13.1 Participant assessment of success by analysing scores and scales	1		Risk Ratio (M‐H, Random, 95% CI)	Totals not selected
13.1.1 4 weeks	1		Risk Ratio (M‐H, Random, 95% CI)	Totals not selected
13.1.2 8 weeks	1		Risk Ratio (M‐H, Random, 95% CI)	Totals not selected
13.1.3 12 weeks	1		Risk Ratio (M‐H, Random, 95% CI)	Totals not selected
13.1.4 16 weeks	1		Risk Ratio (M‐H, Random, 95% CI)	Totals not selected
13.1.5 20 weeks	1		Risk Ratio (M‐H, Random, 95% CI)	Totals not selected
13.1.6 24 weeks	1		Risk Ratio (M‐H, Random, 95% CI)	Totals not selected
13.2 Physician assessment of success by analysing scores and scales	1		Risk Ratio (M‐H, Random, 95% CI)	Totals not selected
13.2.1 4 weeks	1		Risk Ratio (M‐H, Random, 95% CI)	Totals not selected
13.2.2 8 weeks	1		Risk Ratio (M‐H, Random, 95% CI)	Totals not selected
13.2.3 12 weeks	1		Risk Ratio (M‐H, Random, 95% CI)	Totals not selected
13.2.4 16 weeks	1		Risk Ratio (M‐H, Random, 95% CI)	Totals not selected
13.2.5 20 weeks	1		Risk Ratio (M‐H, Random, 95% CI)	Totals not selected
13.2.6 24 weeks	1		Risk Ratio (M‐H, Random, 95% CI)	Totals not selected
13.3 Total adverse events	1		Risk Ratio (M‐H, Random, 95% CI)	Totals not selected